Irinotecan hydrochloride
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1996
- First approval year
- 1996
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Irinotecan hydrochloride
- Molecular weight
- 677.19
- Structure (SMILES)
- CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O
- campto
- Campto
- camptosar
- Camptosar
- irinotecan hydrochloride
- Irinotecan hydrochloride
- irinotecan hydrochloride component of xeliri
- Irinotecan hydrochloride component of xeliri
- onivyde
- Onivyde
- Onivyde pegylated liposomal (previously known as onivyde)
- onivyde pegylated liposomal previously known as onivyde
- (+)-7-ETHYL-10-HYDROXYCAMPTOTHECINE 10-(1,4'-BIPIPERIDINE)-1'-CARBOXYLATE, MONOHYDROCHLORIDE, TRIHYDRATE
- (1,4'-BIPIPERIDINE)-1'-CARBOXYLIC ACID, 4,11-DIETHYL-3,4,12,14-TETRAHYDRO-4-HYDROXY-3,14-DIOXO-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-9-YL ESTER, MONOHYDROCHLORIDE, TRIHYDRATE, (S)-
- 1 4 bipiperidine 1 carboxylic acid 4 11 diethyl 3 4 12 14 tetrahydro 4 hydroxy 3 14 dioxo 1h pyrano 3 4 6 7 indolizino 1 2 b quinolin 9 yl ester monohydrochloride trihydrate s
- 7 ethyl 10 hydroxycamptothecine 10 1 4 bipiperidine 1 carboxylate monohydrochloride trihydrate
- bevacizumab and cpt 11 and carboplatin
- camptosar
- Camptosar®
- cpt 11
- CPT- 11
- CPT-11
- dq 2805
- DQ-2805
- Irinotecan (CPT-11) liposome
- irinotecan anhydrous free base
- Irinotecan anhydrous free-base
- irinotecan hydrochloride
- Irinotecan hydrochloride
- IRINOTECAN HYDROCHLORIDE [MART.]
- IRINOTECAN HYDROCHLORIDE [ORANGE BOOK]
- IRINOTECAN HYDROCHLORIDE [USAN]
- IRINOTECAN HYDROCHLORIDE [USP MONOGRAPH]
- IRINOTECAN HYDROCHLORIDE [USP-RS]
- IRINOTECAN HYDROCHLORIDE [VANDF]
- irinotecan hydrochloride anhydrous
- Irinotecan hydrochloride anhydrous
And 34 more, listed on the interactive page.
- CAS registry numbers
- 136572-09-3
- ChEMBL ID
- CHEMBL3989514
- InChIKey
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N
- RxNorm IDs (RxCUI)
- 153329
- FDA ingredient codes (UNII)
- 042LAQ1IIS
- 60837
- 46911859
- Applicant
- PFIZER INC
- Approval date
- 14 Jun 1996
- Application number
- NDA020571
- Patents
- 14
- Designations
- 3
- Earliest recorded loss of exclusivity
- 15 Oct 2036
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- Yes
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- Yes
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- irinotecan
- Type
- Synthetic organic
- Drug name stem
- -tecan
Administration routes
- Parenteral
Mechanisms of action
- Mechanism
- DNA topoisomerase I inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 1
- Protein identifier
- P11387
Open Targets mechanisms
- Mechanism
- DNA topoisomerase I inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 1
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Sarcoma, Ewing
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000174
- Subject identifier
- D012512
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Lymphoma, B-Cell, Marginal Zone
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000191
- Subject identifier
- D018442
- Condition
- Adenocarcinoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000228
- Subject identifier
- D000230
- Condition
- Rhabdomyosarcoma, Alveolar
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000248
- Subject identifier
- D018232
- Condition
- Immunoblastic Lymphadenopathy
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000255
- Subject identifier
- D007119
- Condition
- Burkitt Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000309
- Subject identifier
- D002051
- Condition
- Carcinoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Rhabdomyosarcoma, Embryonal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000437
- Subject identifier
- D018233
- Condition
- Ganglioneuroblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000502
- Subject identifier
- D018305
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Leukemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neuroblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Osteosarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000637
- Subject identifier
- D012516
- Condition
- Sarcoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000707
- Subject identifier
- D002294
And 88 more, listed on the interactive page.
- Condition identifier
- EFO_0000174
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000178
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000228
- Condition identifier
- EFO_0000313
- Condition identifier
- EFO_0000365
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001071
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002916
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003860
- Condition identifier
- EFO_0004142
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005221
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005922
- Highest recorded phase
- 1
- Condition identifier
- EFO_0006859
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000044
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000158
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000359
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000657
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001471
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001480
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 2
And 79 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Event
- abdominal pain
- Reports
- 178
- Reporting signal score
- 65.8122
- Event
- bone marrow failure
- Reports
- 103
- Reporting signal score
- 155.33
- Event
- cholangitis
- Reports
- 34
- Reporting signal score
- 62.1355
- Event
- cholinergic syndrome
- Reports
- 26
- Reporting signal score
- 94.086
- Event
- decreased appetite
- Reports
- 161
- Reporting signal score
- 85.7839
- Event
- dehydration
- Reports
- 169
- Reporting signal score
- 121.245
- Event
- dermatitis acneiform
- Reports
- 39
- Reporting signal score
- 79.552
- Event
- diarrhoea
- Reports
- 831
- Reporting signal score
- 755.289
- Event
- disease progression
- Reports
- 180
- Reporting signal score
- 177.451
- Event
- febrile neutropenia
- Reports
- 234
- Reporting signal score
- 333.067
- Event
- headache
- Reports
- 36
- Reporting signal score
- 56.8454
- Event
- hypokalaemia
- Reports
- 76
- Reporting signal score
- 54.4059
- Event
- interstitial lung disease
- Reports
- 98
- Reporting signal score
- 92.7852
- Event
- leukopenia
- Reports
- 137
- Reporting signal score
- 145.896
- Event
- mucosal inflammation
- Reports
- 68
- Reporting signal score
- 69.7848
- Event
- myelosuppression
- Reports
- 128
- Reporting signal score
- 316.109
- Event
- nausea
- Reports
- 397
- Reporting signal score
- 85.6013
- Event
- neoplasm progression
- Reports
- 78
- Reporting signal score
- 106.93
- Event
- neuropathy peripheral
- Reports
- 155
- Reporting signal score
- 131.286
- Event
- neutropenia
- Reports
- 322
- Reporting signal score
- 332.777
- Event
- neutrophil count decreased
- Reports
- 169
- Reporting signal score
- 267.024
- Event
- paronychia
- Reports
- 29
- Reporting signal score
- 56.0871
- Event
- peripheral sensory neuropathy
- Reports
- 52
- Reporting signal score
- 103.981
- Event
- pyrexia
- Reports
- 247
- Reporting signal score
- 74.7557
- Event
- stomatitis
- Reports
- 128
- Reporting signal score
- 152.629
And 2 more, listed on the interactive page.
- NCT00002759
- NCT00003245
- NCT00003368
- NCT00002902
- NCT00002939
- NCT00003109
- NCT00003710
- NCT00003711
- NCT00003742
- NCT00004051
- NCT00004919
- NCT00004923
- NCT00005068
- NCT00005791
- NCT00006000
- NCT00006095
- NCT00006465
- NCT00006485
- NCT00008424
- NCT00016861
- NCT00020488
- NCT00020748
- NCT00021073
- NCT00024141
- NCT00024284
And 397 more, listed on the interactive page.
- Dose
- 125 mg/m2
- Route
- Intravenous
- How often
- Every 6 weeks
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 1
- Polar surface area
- 114.2
- Calculated partition coefficient (ALogP)
- 4.09
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 4
- Heavy atoms
- 47
- Molecular formula
- C33H45ClN4O9
- Monoisotopic mass
- 676.2875067
- Natural product
- No
- 0009-0082
- 0009-0112
- 0009-7529
- 0143-9583
- 0143-9701
- 0143-9702
- 16714-027
- 16714-131
- 25021-230
- 45963-614
- 50742-401
- 50742-402
- 55150-352
- 55150-353
- 55150-354
- 55150-355
- 61703-349
- 63323-193
- 68001-480
- 68083-381
- 68083-382
- 70700-169
- 70700-170
- 15054-0043
- 60505-6128
And 4 more, listed on the interactive page.
- Recorded assays
- 50
- Active assays
- 13
- Confirmatory
- Screening
- Topoisomerase I Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE I.
Related records
Trials (1,281)
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
- 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- 9-ING-41 in Patients With Advanced Cancers
- 9-ING-41 in Pediatric Patients With Refractory Malignancies.
- A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)
- A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
- A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
- A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.
- A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
- A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
- A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer
- A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
- A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma
- A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
- A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
- A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC
Approved for (5)
- Adenocarcinoma
- Carcinoma
- Exocrine pancreatic carcinoma
- Malignant pancreatic neoplasm
- Pancreatic neoplasm
In development for (108)
- Adult glioblastoma Phase 2
- Adult T-cell leukemia/lymphoma Phase 1
- Alveolar rhabdomyosarcoma Phase 3
- Anaplastic astrocytoma Phase 2
- Anaplastic large cell lymphoma Phase 1
- Anaplastic oligodendroglioma Phase 2
- Angioimmunoblastic T-cell lymphoma Phase 1
- Anus cancer Phase 1
- Appendix carcinoma Phase 1
- B-cell chronic lymphocytic leukemia Phase 1
- Basal cell carcinoma Phase 1
- Biliary tract cancer Phase 2
- Brain neoplasm Phase 2
- Breast cancer Phase 2
- Burkitt lymphoma Phase 1
- Cancer Phase 2
- Carcinoid tumor Phase 2
- Carcinoma of esophagus Phase 2
- Central nervous system neoplasm Phase 2
- Cerebral astrocytoma Phase 2
Targets (1)
- TOP1 DNA topoisomerase I inhibitor